1. Introduction {#sec1}
===============

The application of natural compounds in the treatment of refractory diseases is a new trend in modern clinical medicine. Because of their satisfactory efficacy in clinic and low toxicity, more natural products are being used as alternative treatments for many diseases. Many hepatoprotective monomers are derived from natural herbs, especially those from China. Glycyrrhizic acid (GA) is an example of one of these hepatoprotective compounds.

The traditional Chinese medicine Gancao (licorice root) is the dried roots of*Glycyrrhiza uralensis* Fisch (licorice),*G. inflata* Bat., or*G. glabra* L. Gancao which was first described in the Chinese book "Shen Nong Ben Cao Jing" in 200 A.D. as an antidote to toxic substances, ache, and other diseases. Gancao can complement other drugs to reduce toxicity and increase efficacy. The traditional use of Gancao involves a decoction of dried plant roots and stems. Some of the possible therapeutic properties of Gancao include antiarthritic \[[@B1]\], antiallergic \[[@B2]\], antiviral \[[@B3]\], antihepatotoxic \[[@B4]\], anticholinergic \[[@B5]\], antiestrogenic \[[@B6]\], anti-inflammatory \[[@B6]\], antileukemogenic \[[@B7]\], and anticarcinogenic effects \[[@B8]\]. It is commonly used for the treatment of acute and chronic liver injury, viral hepatitis, hepatic steatosis, liver fibrosis, hepatoma, viral myocarditis \[[@B9]\], and other diseases like psoriasis \[[@B10]\] or prostate cancer \[[@B11]\].

The known chemical components of Gancao include saponins (mainly glycyrrhizin (GA), 3.63--13.06%), flavonoids (1.5%), coumarin, alkaloids, polysaccharides, sitosterol, and amino acids \[[@B12]\]. GA ([Figure 1](#fig1){ref-type="fig"}) and glycyrrhetinic acid ([Figure 2](#fig2){ref-type="fig"}) are well-characterized components of Gancao. GA has been developed as a hepatoprotective drug in China and Japan. GA can generate glycyrrhetinic acid through metabolic processes in the human body. Therefore, the pharmacological effects of GA are essentially the same as glycyrrhetinic acid \[[@B13]\]. GA, also called glycyrrhizin, is a triterpene glycoside from licorice root (*Glycyrrhiza glabra*) and consists of one molecule of 18*β*-glycyrrhetinic acid and two molecules of glucuronic acid (18*β*-glycyrrhetinic acid-3-O-*β*-D-glucuronopyranosyl-(1 → 2)-beta-D-glucuronide) \[[@B14], [@B15]\]. Glycyrrhizin is considered to be the major active component of Gancao as demonstrated by studies with experimental animal models \[[@B16]\] and clinical studies \[[@B17]\]. GA has been used clinically for more than 20 years in patients with chronic hepatitis in China and Japan \[[@B18]\] and shows a satisfactory therapeutic effect in many other diseases. GA is also widely used as a sweetening and flavoring agent in food.

GA is a main substance of licorice, which is one of the most important substances utilized as traditional medicine for almost 2000 years. Moreover, GA was reported to have antiallergic, antiviral, and anti-inflammatory activities. GA was also found to suppress the rise in fasting blood glucose and insulin levels and improve glucose tolerance. Additionally, GA may act as an antidiabetic substance without inducing side effects, although the mechanism is unclear \[[@B19]\].

GA can form two epimers: *α*-GA and *β*-GA ([Figure 3](#fig3){ref-type="fig"}). *α*-GA is derived from *β*-GA by isomerization, and the *α*- and *β*-forms differ only in their C~18~--H--,*trans*-, and*cis*-configuration, respectively. Some scholars examined their distribution characteristics in rat tissue and found that the concentrations of *α*-GA in the liver and duodenum were significantly higher than those of *β*-GA after*i.v.* administration. However, the concentrations of *α*-GA in the other tissues were lower than or similar to those of *β*-GA and declined rapidly. This indicates that the protective and anti-inflammatory effects of *α*-GA on the liver may be better than those of *β*-GA \[[@B20]\].

Several clinical studies reported that GA was efficacious in the treatment of various types of inflammation (mainly in liver \[[@B21]--[@B30]\] ([Table 1](#tab1){ref-type="table"}), but also in lung, kidney, intestine, and spinal cord \[[@B31]\]). The most common use of GA is in the treatment of liver disease \[[@B32]\]. GA can reduce steatosis and necrosis of liver cells significantly \[[@B33]\] to inhibit the inter-interstitial inflammation and liver fibrosis and promote cell regeneration. GA has few side effects and is therefore considered to be a drug worth attention and promotion for liver disease.

2. Mechanisms of GA Effects {#sec2}
===========================

2.1. Inhibition of Hepatic Apoptosis and Necrosis {#sec2.1}
-------------------------------------------------

Tumor necrosis factor-alpha (TNF-*α*) is an important cytokine, which is a key mediator of hepatic apoptosis and necrosis in LPS/D-GaAlN-induced liver failure \[[@B34]\]. Plasma TNF-*α* level is also elevated in patients with chronic hepatitis caused by hepatitis B viral \[[@B35]\] and acute alcoholic hepatitis \[[@B36]\]. Therefore, TNF-*α* plays a key role in the pathogenesis of not only endotoxin-induced experimental liver injury but also many human liver diseases. Caspase-3 activation is an indicator of almost all apoptosis systems \[[@B37]\]. GA has anti-inflammatory and antiapoptotic effects via suppression of TNF-*α* and caspase-3 and these are used to explain the hepatoprotective effect of GA ([Table 2](#tab2){ref-type="table"}) \[[@B38]\]. GA also significantly inhibits the release of cytochrome C from mitochondria into the cytoplasm. The anti-inflammatory activity of GA may rely on the inhibition of release of TNF-*α*, myeloperoxidase activity, and translocation of nuclear factor-*κ*B (NF-*κ*B) into the nuclei. GA also upregulated the expression of proliferating cell nuclear antigen, implying that it might be able to promote regeneration of liver injury \[[@B39]\]. Activated Kupffer cells are involved in ischemia-reperfusion- (I/R-) induced liver injury and high-mobility group box 1 (HMGB1) production. GA was shown to inhibit HMGB1 production by Kupffer cells and prevented I/R-induced liver injury \[[@B40]\]. GA could also alleviate I/R-induced \[[@B41]\] and spinal cord \[[@B42]\] injury via this mechanism. In addition, GA conjugates free radicals, which might explain the protective action of GA \[[@B43]\]. For example, GA can be an effective chemopreventive agent against lead acetate mediated hepatic oxidative stress in rats because it binds lead \[[@B44]\]. In concanavalin A- (ConA-) induced mouse model, GA alleviated ConA-induced inflammation and fibrosis progression in livers via inhibition of CD4+ T cell proliferation in response to ConA via the Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and phosphoinositide 3-kinase (PI3K)/AKT pathways \[[@B45]\].

2.2. Anti-Inflammation and Immunity Regulation {#sec2.2}
----------------------------------------------

GA suppressed interleukin-6 (IL-6) and TNF-*α* production induced by the lipid A moiety of lipopolysaccharides (LPS) in RAW264.7 cells. It inhibited lipid A-induced NF-*κ*B activation in Ba/F3 cells expressing toll-like receptor 4 (TLR4)/myeloid differentiation protein-2 (MD-2), cluster of differentiation 14 (CD14), and bone marrow-derived macrophages (BMMs). GA also inhibited activation of mitogen-activated protein kinase (MAPKs), including JNK, p38 protein, and ERK in BMMs. In addition, GA inhibited NF-*κ*B activation and IL-6 production induced by paclitaxel, a nonbacterial TLR4 ligand. It attenuated the formation of the LPS-TLR4/MD-2 complexes, resulting in inhibition of homodimerization of TLR4. Therefore, GA modulated the TLR4/MD-2 complex at the receptor level, leading to suppression of LPS-induced activation of signaling cascades and cytokine production. This indicates that GA can attenuate inflammatory responses and modulate innate immune responses \[[@B46]\]. Moreover, GA can prevent the activation of signal transducers and activators of transcription-3 (STAT-3), reduce the upregulation of intercellular cell adhesion molecule (ICAM-1) and P-selectin expression, reduce formation of poly(adenosine diphosphate-ribose) (PAR) and nitrotyrosine, and reduce polymorphonuclear neutrophil (PMN) infiltration. Some observations suggest that broad anti-inflammatory activity of GA is mediated by interaction with the lipid bilayer, thereby attenuating receptor mediated signaling \[[@B47]\]. GA inhibited the lytic pathway of the complement system and may prevent tissue injury caused by the membrane attack complex. Therefore, GA could be a potent agent for suppressing complement-dependent tissue injury in autoimmune and inflammatory diseases \[[@B48]\]. GA can suppress systemic inflammatory response syndrome (SIRS) associated anti-inflammatory response manifestation via inhibition of CC chemokine ligand 2 (CCL2) production by PMN. It may also have the potential to inhibit anti-inflammatory response-associated opportunistic infections in critically ill patients with severe SIRS \[[@B49]\]. There are also other studies that indicated the same anti-inflammatory mechanisms of GA \[[@B50]\].

2.3. Antiviral Effects {#sec2.3}
----------------------

The antiviral mechanisms of GA mainly include the inhibition of viral replication and immunity regulation. GA affects cellular signaling pathways such as protein kinase C and casein kinase II and transcription factors such as activator protein 1 and NF-*κ*B. Furthermore, nitrous oxide (NO) inhibits replication of several viruses like Japanese encephalitis virus 4 (a member of the Flaviviridae family), which can also be inhibited by GA. The powerful anti-inflammatory capabilities of GA make it effective in the treatment of various types of hepatitis like viral hepatitis and nonalcoholic hepatitis. GA was found to inhibit the replication of the SARS-associated virus \[[@B51]\]. In the treatment of HCV (hepatitis C virus) infection, GA can inhibit HCV full-length viral particles and HCV core gene expression or function in a dose-dependent manner and have a synergistic effect with interferon \[[@B52]\]. GA is also involved in biliary secretion and excretion. GA can increase hepatic glutathione levels by the inhibition of biliary excretion of glutathione partly through the inhibition of MRP2 \[[@B53]\], an efflux transporter located at the canalicular membrane of a hepatocyte. MRP2 translocates glutathione, LTC4, bilirubin, methotrexate (MTX), glucuronide (e.g., estradiol-17-*β*-glucuronide \[E~2~17G\]), or sulfate conjugates and other organic anions from a hepatocyte into the bile canaliculus \[[@B54]--[@B58]\].

GA can activate certain immune functions, such as IFN production, augmentation of NK cell activity, and modulation of the growth response of lymphocytes via augmentation of IL-2 production \[[@B59]\]. GA can enhance immune function in mice \[[@B60]\]. GA treatment could significantly reduce blood immunoglobulin E (IgE), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), NO, TNF-*α* levels, and nitrous oxide synthase (NOS) activity dose-dependently. GA could also enhance blood immunoglobulin A (IgA), immunoglobulin G (IgG), immunoglobulin M (IgM), interleukin-2 (IL-2), and interleukin-12 (IL-12) levels in AR mice. Gr-1^+^CD11^+^b cells are responsible for numerous pathological processes such as T cell dysfunction after severe trauma or major surgery, leading to increased susceptibility to infection \[[@B61]\]. These cells exercise an inhibitory effect on MBD-1 production of EKs mediated via the suppressor molecules CCL-2 and IL-10. GA acts as a potent inhibitor of these cells and therefore restores MBD-1 levels. This restoration affects T cell dysfunction \[[@B62]\]. In thermally injured mice, GA regulates the burn-associated type 2 T cell responses to recover IL-12 and make it unresponsive, thus restoring the impaired cells \[[@B63]\]. GA acts as a promoter of the late signal transduction of T lymphocytes for IL-2 production. The balance between augmenting and suppressing effects might be dependent on the level of stimulation and stage of the cell. Therefore, this determines quality and quantity of the immunomodulatory action of GA \[[@B64]\]. In blood and nasal mucosa, GA consumption decreases antioxidant enzyme activity, lipid peroxidation, Glutathione levels, and IL-4 levels and enhances IFN-*γ*, thus protecting the nasal mucosa from oxidative injury and improving immunity activity \[[@B65]\].

GA interferes with some viruses, such as H5N1 \[[@B66]\]. The replication and virus-induced proinflammatory gene expression include inhibition of the virus-induced formation of reactive oxygen species and reduced activation of NF-*κ*B, JNK, and p38, which are redox-sensitive signaling events known to be relevant for replication.

2.4. Antitumor Effects {#sec2.4}
----------------------

CYP enzymes are mainly found in the liver and bowel wall. They are responsible for the bulk of phase I or oxidative metabolism of xenobiotics including dietary toxins, carcinogens, mutagens, and drugs. Administration of GA was able to significantly induce CYP content, which reduces the incidence of cancer \[[@B67]\]. GA can also protect against aflatoxin-induced oxidative stress. The protective effect is likely from its capacity to inhibit the metabolic activation of hepatotoxin, a critical factor in the pathogenesis of chemical-induced carcinogenicity \[[@B68]\]. O-carboxymethyl chitosan nanoparticles (CMCNP) modified by GA with various substitution degrees can efficiently deliver paclitaxel (PTX) to hepatocellular carcinomas (HCC). CMCNP-GA significantly facilitated the increased accumulation of PTX in hepatic tumor tissues and the targeted delivery of PTX to hepatoma carcinoma cells, which resulted in remarkably enhanced*in vitro* cytotoxicity and*in vivo* antitumor efficacy \[[@B69]\]. In a diethylnitrosamine-treated experimental animal study, as a chemopreventive agent of HCC, modulation of cell proliferation and apoptosis by GA may be associated with inhibition of HCC. Therefore, GA treatment may inhibit the occurrence of HCC \[[@B70]\].

2.5. Inductive Effect of Liver Enzyme Activity {#sec2.5}
----------------------------------------------

Some studies showed that GA has an inductive effect on CYP3A activity. Therefore, clinicians should pay attention to other drugs catalyzed by CYP3A, especially those substrates with a narrow therapeutic range such as cyclosporine A, to avoid possible clinically significant interactions with GA \[[@B71]\]. Some studies revealed that the area under concentration-time curve and the mean retention time of methotrexate (MTX) were significantly increased by GA, which increases the adverse reactions of MTX \[[@B72]\]. MTX is an antifolate agent, anticancer agent, and immunosuppressant and is commonly used for anticancer chemotherapy \[[@B73]\], rheumatoid arthritis \[[@B74]\], and severe psoriasis \[[@B75]\]. The adverse reactions of MTX include nausea, vomiting, diarrhea, and hepatotoxicity \[[@B76], [@B77]\]. A case report showed that combined administration of GA and cilostazol caused pseudoaldosteronism \[[@B78]\]. Therefore, the concurrent use of GA with MTX or cilostazol is not recommended. One report shows a case of hypokalemic rhabdomyolysis secondary to chronic GA intoxication \[[@B79]\]. GA ingestion could therefore potentially aggravate hypokalemia in patients with chronic laxative abuse \[[@B80]\], indicating that the use of GA in hypokalemia should be treated with caution.

3. Other Pharmacological Activities {#sec3}
===================================

GA is effective in combating hyperglycemia and associated pathological complications such as hyperlipidemia, abnormal histoarchitectures of different organs, and oxidative stress including hemoglobin-induced iron-mediated free radical reactions. The effects of GA on diabetes-associated changes are almost comparable with those of glibenclamide, a standard antihyperglycemic drug, suggesting a possible use of the herbal agent as a drug to prevent complications of diabetes mellitus \[[@B81]\]. Furthermore, GA regulates renal function through the regulation of water channels \[[@B82]\], and GA administration ameliorates the renal concentrating ability and structural lesions in renal tissues in rats with early-phase of ischemia-acute renal failure \[[@B83]\]. As a reduction inhibitor, GA reduces the therapeutic loss of methylprednisolone produced from methylprednisolone 21-sulfate sodium in the large intestine, thus improving the therapeutic property of the prodrug against inflammatory bowel disease \[[@B84]\]. GA also offers protection from the damage induced by UVB radiation in humans. Therefore, it could be considered as a promising agent for addition to topical formulations for the prevention of skin cancer \[[@B85]\]. GA significantly alleviates asthma symptoms \[[@B86]\], inhibits lung inflammation \[[@B87]\], and relieves acute lung injury \[[@B35], [@B88]\]. It can directly affect cardiac performance and play a role in myocardial and coronary protection in the presence of cardiovascular diseases \[[@B89]\]. GA may prevent brain tissue damage \[[@B90]\], can be a putative therapeutic drug for neurodegenerative diseases associated with cognitive deficits and neuroinflammation such as Alzheimer\'s disease \[[@B91]\], and could suppress ocular hypertension with potential therapeutic effects in eye disease \[[@B92]\]. GA improves resistance to*C. albicans* infection by inducing CD4+ T cells, which suppress type 2 cytokine production by Th2 cells \[[@B93]\]. GA inhibits activated macrophage (M2M) generation stimulated with neutrophils. The regulation of neutrophil-associated M2M generation by GA may provide a new therapeutic strategy, which could influence the outcome of certain severe infections in hosts with M2M generation \[[@B94]\].

4. Drugs That Include GA {#sec4}
========================

Drugs made with GA have been on the market for many years, and most have important therapeutic uses. Magnesium isoglycyrrhizinate injection (TianQing GanMei, Chia Tai Tainqing, JiangSu, China) is one example of a drug with GA. Magnesium isoglycyrrhizinate is an effective and safe treatment for chronic liver diseases \[[@B95]\] and is capable of slowing down the progress of pulmonary fibrosis \[[@B96]\]. Moreover, diammonium glycyrrhizinate enteric-coated capsules (TianQing GanPing, Chia Tai Tainqing, JiangSu, China) and diammonium glycyrrhizinate injection (GanLiXin, Chia Tai Tainqing, JiangSu, China) are used for acute and chronic hepatitis associated with elevated alanine aminotransferase. Stronger neo-minophagen C (SNMC, Minophagen Pharmaceutical, Tokyo, Japan) is often used in the treatment of chronic liver disease and can improve liver dysfunction \[[@B97]\]. SNMC is a compound GA tablet that includes GA (2 mg) with glycine acid (20 mg) and L-cysteine hydrochloride (1 mg). SNMC has anti-inflammatory, antiallergic, steroid-like, anticomplementary, and immunoregulatory effects.

5. GA Combined with Matrine {#sec5}
===========================

GA combined with matrine (Mat) can improve CCL4-induced liver fibrosis effectively. This is evidenced by lower levels of collagen, hyaluronic acid (HA), and laminin (LN), less hepatic stellate cells (HSC) proliferation, collagen I, and HA levels secreted by HSC*in vitro* with combined therapy compared with GA or Mat alone. GA combination with Mat could protect liver cells and inhibit hepatic fibrosis and may therefore be a safe and effective strategy for improving hepatic fibrosis \[[@B98]\]. In an animal model, GA combined with Mat reduced the mortality of acetaminophen overdosed mice, attenuated acetaminophen-induced hepatotoxicity, and reduced the number and area of y-GT positive foci, thus protecting liver function and preventing HCC from occurring \[[@B99]\]. Additionally, the combination of GA and cyclosporine was an effective treatment for nonsevere aplastic anemia \[[@B100]\].

6. Common Derivatives of Glycyrrhizin {#sec6}
=====================================

Glycyrrhetinic acid (3*β*-hydroxy-11-oxo-oleana-12-en-28-oic acid), the aglycone of GA, stimulates glucose-induced insulin secretion in isolated pancreatic islets. Glycyrrhetinic acid treatment enhances plasma insulin levels and reduces the levels of gluconeogenic enzymes in liver. It is a pentacyclic triterpene acid with numerous biological activities, including anti-inflammatory \[[@B101]\], antiviral \[[@B102]\], antiallergic \[[@B103]\], and antitumor proliferative effects \[[@B104]\].

Glycyrrhetinic acid restrains the proliferation of skin tumors in mice and human breast cancer cells (MCF7) and induces apoptosis of cancer cells. The mechanism of apoptosis might be via increased free Ca^2+^ level in the cells \[[@B105]\]. Mizushina et al. \[[@B106]\] demonstrated that glycyrrhetinic acid potently inhibited the activity of mammalian polymerases, including pol *λ*. Glycyrrhetinic acid also reduced TNF-*α* production and NF-*κ*B activation and suppressed mouse ear inflammation stimulated by tissue plasminogen activator. Therefore, glycyrrhetinic acid could be an anti-inflammatory agent based on pol *λ* inhibition.

Another licorice acid derivative is 18*β*-glycyrrhetic acid. The triterpene structure of the HMGB1-binding compound is capable of binding to HMGB1 and altering its proinflammatory properties, inhibiting HMGB1-dependent cyclooxygenase (COX) 2 induction \[[@B107]\]. 18*β*-glycyrrhetic acid has significant antiviral activity against rotavirus replication*in vitro*, and studies to determine whether 18*β*-glycyrrhetic acid attenuates rotavirus replication*in vivo* are underway, although the exact mechanism is unclear. However, some reports show that 18*β*-glycyrrhetic acid inhibits NF-*κ*B activation, which has been interpreted as 18*β*-glycyrrhetic acid-mediated regulation of the inflammatory response \[[@B108]\]. 18*β*-glycyrrhetinic acid can also inhibit the activity of tyrosine and prevent melanin growth and whitening. Some reports show that 18*β*-glycyrrhetinic acid is likely responsible for amelioration of dysfunction of glutamate transport in astrocytes, and the inhibition of protein kinase C activity might be related to its pharmacological efficacy \[[@B109]\].

7. Conclusions and Future Perspectives {#sec7}
======================================

This review summarized the efficacy of GA in liver disease from clinical trials and its mechanisms of action*in vitro* and*in vivo*. Studies indicate that GA could modulate various molecular pathways in liver disease. There are numerous patents for drugs including GA ([Table 3](#tab3){ref-type="table"}). Studies described here highlight the use of GA as a novel chemopreventive agent for liver injury. It is expected that future studies with GA will help to define various molecular mechanisms and targets for inflammation and steatosis. At present, the number of multicenter, large sample, randomized, double-blind, controlled chemoprevention clinical trials with GA is very limited. Extensive clinical research is warranted to evaluate the safety and chemopreventive efficacy of GA alone or in combination with chemotherapy agents.
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###### 

Clinical trials using compound glycyrrhizic acid injection.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Experimental drugs             Dose and course of treatment                                                                   Combined medication      Case/control   Disease type                                                                                                  Indications and symptoms                                                                 Efficacy                                                                                                                                                                                                                                                          Positive control                            Side effect                                                       Reference
  ------------------------------ ---------------------------------------------------------------------------------------------- ------------------------ -------------- ------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------- ----------------------------------------------------------------- ------------
  Glycyrrhizin                   200 mg + NaCl\                                                                                 Prednisolone\            31/14          Acute onset autoimmune hepatitis (AIH)                                                                        Fever, general malaise, fatigue, nausea, vomiting, and right upper quadrant discomfort   Recovery rate was higher in the SNMC group than in the SNMC + CS group (*P* = 0.035)                                                                                                                                                                              Glycyrrhizin and corticosteroids (CS)       None                                                              \[[@B21]\]
                                 100 mL, i.v., q.d., 4 weeks                                                                    (20--60 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Glycyrrhizin                   200 mg, i.v., q.d., 52 weeks                                                                   None                     374/129        Chronic hepatitis C                                                                                           Inflammatory effect                                                                      The proportion of patients with ALT reduction ≥50% after 12 weeks was significantly higher with 5×/week glycyrrhizin (28.7%, *P* \< 0.0001) and 3×/week glycyrrhizin (29.0%, *P* \< 0.0001) compared with placebo (7.0%).                                         Placebo-controlled                          None                                                              \[[@B22]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Glycyrrhizin                   200 mg + NaCl\                                                                                 None                     69/13          Chronic hepatitis C                                                                                           HCV and HCV-RNA positive;\                                                               The mean percentage ALT decrease from baseline at the end of treatment was 26% and 47% for the three times per week and six times per week treatment group, respectively (both *P* \< 0.001 versus placebo)                                                       Placebo-controlled                          None                                                              \[[@B23]\]
                                 100 mL, i.v., 6c/week, 4 weeks                                                                                                                                                                                                                       serum ALT at least 1.5 times;\                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                      liver fibrosis or cirrhosis                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Glycyrrhizin                   200 mg + NaCl\                                                                                 None                     453/109        Hepatocellular carcinoma (HCC) occurs in patients with hepatitis C virus-RNA positive chronic liver disease   Inflammatory effect after HCC                                                            Patients treated with SNMC; the 10-year HCC appearance rates in histologic Stages I, II, and III were 3%, and 13%, respectively                                                                                                                                   Other herbal medicines                      None                                                              \[[@B24]\]
                                 100 mL, i.v., q.d. for 8 weeks, then 2--7c/week for 2--16 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Glycyrrhizin                   200 mg + NaCl\                                                                                 None                     1249/796       Interferon-resistant hepatitis C                                                                              Chronic hepatitis effect                                                                 Crude carcinogenesis rates in the treated and untreated group were 13.3%, 26.0% at the fifth year and 21.5% and 35.5% at the 10th year, respectively (*P* = 0.021)                                                                                                Others without glycyrrhizin therapy         Hypertension skin rash without itching                            \[[@B25]\]
                                 100 mL, i.v., q.d., 0.1--14.5 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Diammonium glycyrrhizinate     150 mg + 5--10% glucose injection liquid 250 mL, i.v., q.d., 1 month, 1-2 cycles               None                     629/127        Chronic hepatitis, liver cirrhosis                                                                            Fatigue, gastrointestinal symptoms, and discomfort in liver area                         After 17-day therapy, there are 93.3% patients with ALT normal level in treating group, but 73.3% in contrast group (*P* \< 0.05). At day 10, the patient\'srecovered normal SB were 86.7% in treatment group, but that was 40% in contrast group (*P* \< 0.01)   Compound ammonium glycyrrhetate injection   Headache, facial edema, and blood pressure increased              \[[@B26]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  *β*-glycyrrhetinic acid        80 mg + 10% glucose injection liquid 250 mL, i.v., q.d., 4 weeks, 100 mg, p.o. tid, 12 weeks   None                     80/40          Chronic Hepatitis B                                                                                           Chronic hepatitis effect                                                                 Compared with control group, the TBil, ALT, AST, HA, and IVC are significantly ameliorated in treatment group (*P* \< 0.01)                                                                                                                                       *α*-glycyrrhizic acid                       Edema, blood pressure increased, and serum potassium mildly low   \[[@B27]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Magnesium isoglycyrrhizinate   80 mg + 10% glucose injection liquid 250 mL, i.v., q.d., 4 weeks                               Hepatoprotective drugs   80/40          Chronic Hepatitis B                                                                                           Fatigue, gastrointestinal symptoms, and discomfort in liver area                         Compared with control group, the TBil, ALT, AST are significantly ameliorated in treatment group (*P* \< 0.05)                                                                                                                                                    Diammonium glycyrrhizinate injection        Headache,and blood pressure increased                             \[[@B28]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Magnesium isoglycyrrhizinate   150 mg + 5--10% glucose injection liquid 250 mL, i.v., q.d., 4 weeks                           None                     60/30          Chronic severe hepatitis                                                                                      Fatigue, gastrointestinal symptoms, discomfort in liver area, and yellow urine           Compared with control group, the TBil, PTA, ALT, and AST are significantly ameliorated in treatment group (*P* \< 0.01)                                                                                                                                           Hepatocyte generation drugs                 None                                                              \[[@B29]\]

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Magnesium isoglycyrrhizinate   150 mg + 5--10% glucose injection liquid 250 mL, i.v., q.d., 2 weeks                           None                     56/28          Liver lesion induced by chemotherapy in cancer                                                                Liver injury effect                                                                      Compared with control group, the TBil, PTA, ALT, and AST are significantly ameliorated in treatment group (*P* \< 0.01)                                                                                                                                           Diammonium glycyrrhizinate injection        None                                                              \[[@B30]\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GA: glycyrrhizic acid; TBil: total bilirubin; IVC: type IV collagen; ALT: alanine aminotransferase; AST: aspartate transaminase; PTA: prothrombin time activity.

###### 

Mechanism of action of glycyrrhizin compound chemotherapy.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound                       Pharmacological activities                                                       Mechanisms of action                                                               Reference
  ------------------------------ -------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ----------------------
  Glycyrrhizic acid              Anti-inflammatory\                                                               Regulating the expression of inflammation-related factors;\                        \[[@B46]--[@B49]\]\
                                 antiviral\                                                                       inhibition replication of viral mRNA                                               \[[@B51], [@B110]\]\
                                 inhibition of hepatic fibrosis                                                                                                                                      \[[@B45]\]

                                                                                                                                                                                                     

  Compound glycyrrhizin tablet   Improving the liver dysfunction\                                                 Regulating the expression of inflammation-related factors;\                        \[[@B97]\]\
                                 augmented the entire cytotoxic function mediated by hepatic lymphocytes\         promoting the growth of hepatocyte;\                                               \[[@B111]\]\
                                 inhibiting the cascade leading to apoptosis                                      inhibition replication of viral mRNA                                               \[[@B112]\]

                                                                                                                                                                                                     

  Glycyrrhetinic acid            Anti-inflammatory\                                                               Regulating the expression of inflammation-related factors;\                        \[[@B101]\]\
                                 antiviral\                                                                       inhibition replication of viral;\                                                  \[[@B102]\]\
                                 antiallergic\                                                                    inhibition of the expression of sensitizing factors and tumor-associated factor;   \[[@B103]\]\
                                 antitumor proliferation                                                                                                                                             \[[@B104]\]

                                                                                                                                                                                                     

  18*β*-glycyrrhetic acid        Antiviral\                                                                       Regulating the expression of inflammation-related factors;\                        \[[@B109]\]
                                 anti-inflammatory                                                                inhibition replication of viral mRNA                                               

                                                                                                                                                                                                     

  Diammonium glycyrrhizinate     Anti-inflammatory, resistance to biologic oxidation and membranous protection\   Regulating the expression of inflammation-related factors;\                        \[[@B113]\]
                                 neuroprotective effect                                                           regulating the enzymatic reactions\' related oxidation                             

                                                                                                                                                                                                     

  Dipotassium glycyrrhizinate    Anti-inflammatory                                                                Regulating the expression of inflammation-related factors                          \[[@B114]\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Patents of glycyrrhizin extracts.

  Patent                                                                                                                                                                             Patent number
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  Acetylated 18-alpha glycyrrhizic acid and preparation method thereof                                                                                                               CN102351937 A
  Ammoniated glycyrrhizin modified sweetened beverage products                                                                                                                       US2008226787(A1)
  Application of beta-glycyrrhizic acid and derivatives thereof for radiation protection                                                                                             CN102206242 A
  Application of glycyrrhetinic acid and glycyrrhizic acid in preparing medicaments for preventing or treating pulmonary fibrosis                                                    CN101919870 B
  Application of glycyrrhizic acid and glycyrrhetic acid in preparing medicine for inflammatory enteropathy                                                                          CN1846705 A
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